General Information of Drug (ID: DM2MSGF)

Drug Name
ASP9831 Drug Info
Indication
Disease Entry ICD 11 Status REF
Non-alcoholic steatohepatitis DB92.1 Phase 2 [1]
Steatohepatitis DB92 Phase 2 [2]
Cross-matching ID
TTD Drug ID
DM2MSGF

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug(s) Targeting Phosphodiesterase 4 (PDE4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Apremilast DMTWS9E Psoriasis vulgaris EA90 Approved [4]
Oxtriphylline DMLHSE3 Cough MD12 Approved [5]
Roflumilast DMPGHY8 Asthma CA23 Approved [6]
Ibudilast DM4LSPN Castleman's disease 4B2Y Approved [7]
crisaborole DMNVKU6 Atopic dermatitis EA80 Approved [8]
Arofylline DM84AD1 Chronic obstructive pulmonary disease CA22 Phase 3 [9]
ARQ-151 DML61S4 Atopic dermatitis EA80 Phase 3 [10]
SUN13834 DMPK34E Gram-positive bacterial infection 1B74-1G40 Phase 2 [11]
ONO-6126 DMRT28X Chronic obstructive pulmonary disease CA22 Phase 2 [9]
E6005 DM1S489 Atopic dermatitis EA80 Phase 2 [12]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Phosphodiesterase 4 (PDE4) TTV5CGO NOUNIPROTAC Inhibitor [3]

References

1 ClinicalTrials.gov (NCT00668070) A Proof-of-principle Study of Oral Treatment of Non-alcoholic Steatohepatitis With a Novel PDE4 Inhibitor ASP9831 (ASTER). U.S. National Institutes of Health.
2 ClinicalTrials.gov (NCT00668070) A Proof-of-principle Study of Oral Treatment of Non-alcoholic Steatohepatitis With a Novel PDE4 Inhibitor ASP9831. U.S. National Institutes of Health.
3 Lack of efficacy of an inhibitor of PDE4 in phase 1 and 2 trials of patients with nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2014 Oct;12(10):1724-30.e5.
4 Highly selective phosphodiesterase 4 inhibitors for the treatment of allergic skin diseases and psoriasis. Inflamm Allergy Drug Targets. 2007 Mar;6(1):17-26.
5 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
6 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
7 Therapeutic targeting of 3',5'-cyclic nucleotide phosphodiesterases: inhibition and beyond. Nat Rev Drug Discov. 2019 Oct;18(10):770-796.
8 2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76.
9 Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91.
10 Trial of Roflumilast Cream for Chronic Plaque Psoriasis. N Engl J Med. 2020 Jul 16;383(3):229-239.
11 Ocular hypotension induced by topical dopaminergic drugs and phosphodiesterase inhibitors. Eur J Pharmacol. 1994 Jun 2;258(1-2):85-94.
12 Antipruritic effect of the topical phosphodiesterase 4 inhibitor E6005 ameliorates skin lesions in a mouse atopic dermatitis model. J Pharmacol Exp Ther. 2013 Jul;346(1):105-12.